theMednetRegister

Medical Oncology

ESMO 2024   

Questions discussed in this category



Papers discussed in this category

Cardiovascular and interventional radiology, 2022 Feb 04
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Frontiers in oncology, 2022 Aug 24
POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.
The New England journal of medicine, 2024 Sep 15
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Lancet, 2018 Oct 18
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
J. Clin. Oncol., 2019 Jul 22
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Lancet Oncol, 2019 Apr 12
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
N Engl J Med, 2022 Feb 17
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Apr 29
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
The Lancet. Oncology, 2023 Apr
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
The New England journal of medicine, 2024 Mar 07
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 16
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
N Engl J Med,
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Lancet, 2023 Jun 02
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
The New England journal of medicine, 2024 Sep 15
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Nature medicine, 2024 Sep 13
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.
The New England journal of medicine, 2024 Sep 15
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
J Clin Oncol, 2022 Jun 06
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Sep 14
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Related Topics in Medical Oncology

Copyright © 2024 theMednet
All Rights Reserved.